AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
{{expandStatus?'Exit ':''}}Advanced Search
Patients with atrial fibrillation (AF) and prior stroke history have a high risk of cardiovascular events despite anticoagulation therapy. It is unclear whether catheter ablation (CA) has further benefits in these patients.
AF patients with a previous history of stroke or systemic embolism (SE) from the prospective Chinese Atrial Fibrillation Registry study between August 2011 and December 2020 were included in the analysis. Patients were matched in a 1:1 ratio to CA or medical treatment (MT) based on propensity score. The primary outcome was a composite of all-cause death or ischemic stroke (IS)/SE.
During a total of 4.1 ± 2.3 years of follow-up, the primary outcome occurred in 111 patients in the CA group (3.3 per 100 person-years) and in 229 patients in the MT group (5.7 per 100 person-years). The CA group had a lower risk of the primary outcome compared to the MT group [hazard ratio (HR) = 0.59, 95% CI: 0.47–0.74, P < 0.001]. There was a significant decreasing risk of all-cause mortality (HR = 0.43, 95% CI: 0.31–0.61, P < 0.001), IS/SE (HR = 0.73, 95% CI: 0.54–0.97, P = 0.033), cardiovascular mortality (HR = 0.32, 95% CI: 0.19–0.54, P < 0.001) and AF recurrence (HR = 0.33, 95% CI: 0.30–0.37, P < 0.001) in the CA group compared to that in the MT group. Sensitivity analysis generated consistent results when adjusting for time-dependent usage of anticoagulants.
In AF patients with a prior stroke history, CA was associated with a lower combined risk of all-cause death or IS/SE. Further clinical trials are warranted to confirm the benefits of CA in these patients.
Dai H, Zhang Q, Much AA, et al. Global, regional, and national prevalence, incidence, mortality, and risk factors for atrial fibrillation, 1990–2017: results from the Global Burden of Disease Study 2017. Eur Heart J Qual Care Clin Outcomes 2021; 7: 574−582.
Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke 2021; 16: 217−221.
Perera KS, Vanassche T, Bosch J, et al. Global survey of the frequency of atrial fibrillation-associated stroke: Embolic Stroke of Undetermined Source Global Registry. Stro ke 2016; 47: 2197−2202.
Zhao Z, Zhang J, Jiang X, et al. Is endovascular treatment still good for ischemic stroke in real world? A meta-analysis of randomized control trial and observational study in the last decade. Stroke 2020; 51: 3250−3263.
Hayden DT, Hannon N, Callaly E, et al. Rates and determinants of 5-year outcomes after atrial fibrillation-related stroke: a population study. Stroke 2015; 46: 3488−3493.
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373−498.
Benz AP, Hohnloser SH, Eikelboom JW, et al. Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. Eur Heart J 2023; 44: 1807−1814.
Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020; 383: 1305−1316.
Jensen M, Suling A, Metzner A, et al. Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial. Lancet Neurol 2023; 22: 45−54.
Siontis KC, Ioannidis JPA, Katritsis GD, et al. Radiofrequency ablation versus antiarrhythmic drug therapy for atrial fibrillation: meta-analysis of quality of life, morbidity, and mortality. JACC Clin Electrophysiol 2016; 2: 170−180.
Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med 2021; 384: 316−324.
Kuniss M, Pavlovic N, Velagic V, et al. Cryoballoon ablation vs. antiarrhythmic drugs: first-line therapy for patients with paroxysmal atrial fibrillation. Europace 2021; 23: 1033–1041.
Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med 2021; 384: 305−315.
Du X, Ma C, Wu J, et al. Rationale and design of the Chinese Atrial Fibrillation Registry study. BMC Cardiovasc Disord 2016; 16: 130.
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955−962.
Gómez-Outes A, Lagunar-Ruíz J, Terleira-Fernández AI, et al. Causes of death in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 2016; 68: 2508−2521.
Lee SR, Choi EK, Lee SW, et al. Early rhythm control in patients with incident atrial fibrillation who had a prior stroke. JACC Clin Electrophysiol 2023; 9: 1121−1133.
Noseworthy PA, Gersh BJ, Kent DM, et al. Atrial fibrillation ablation in practice: assessing CABANA generalizability. Eur Heart J 2019; 40: 1257−1264.
Lin YS, Wu VC, Wang HT, et al. The implications of catheter ablation for solitary atrial flutter in preventing stroke risk: a nationwide population-based cohort study. Europ ace 2020; 22: 1558−1566.
Bunch TJ, May HT, Bair TL, et al. Five-year impact of catheter ablation for atrial fibrillation in patients with a prior history of stroke. J Cardiovasc Electrophysiol 2018; 29: 221−226.
Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation 2022; 145: e722−e759.
Badin A, Parr AR, Banga S, et al. Patients’ and physicians’ perceptions regarding the benefits of atrial fibrillation ablation. Pacing Clin Electrophysiol 2017; 40: 362−371.
Själander S, Holmqvist F, Smith JG, et al. Assessment of use vs discontinuation of oral anticoagulation after pulmonary vein isolation in patients with atrial fibrillation. JA MA Cardiol 2017; 2: 146−152.
Yang WY, Du X, Jiang C, et al. The safety of discontinuation of oral anticoagulation therapy after apparently successful atrial fibrillation ablation: a report from the Chinese Atrial Fibrillation Registry study. Europace 2020; 22: 90−99.
Wang JR, Du X, Dong JZ, et al. Use of oral anticoagulants and its associated factors among nonvalvular atrial fibrillation patients with new-onset acute ischemic stroke: a report from the China Atrial Fibrillation Registry study. Cl in Cardiol 2022; 45: 60−67.
De Breucker S, Herzog G, Pepersack T. Could geriatric characteristics explain the under-prescription of anticoagulation therapy for older patients admitted with atrial fibrillation? A retrospective observational study. Drugs Ag ing 2010; 27: 807−813.
Turagam MK, Garg J, Whang W, et al. Catheter ablation of atrial fibrillation in patients with heart failure: a meta-analysis of randomized controlled trials. Ann Intern Med 2019; 170: 41−50.
763
Views
49
Downloads
1
Crossref
1
Web of Science
1
Scopus
0
CSCD
Altmetrics
京公网安备11010802044758号